Follow-up of 452 totally implantable vascular devices in cystic fibrosis patients

European Respiratory Journal

Volumn 23, Issue 3, 2004, Pages 430-434

  Munck, Anne ^a   Malbezin, S ^a   Bloch, J ^a   Gerardin, M ^a   Lebourgeois, M ^a   Derelle, J ^c   Bremont, F ^c   Sermet, I ^b   Munck, M R ^c   Navarro, J ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Department of Paediatrics ^*  (France)

Author keywords

Central venous access; Cystic fibrosis; Intravenous antibiotic therapy; Totally implantable vascular access devices

Indexed keywords

AMINOGLYCOSIDE; AMINOPENICILLIN; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; HEPARIN; POLYURETHAN; SILICONE; VANCOMYCIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL OCCLUSION; CANDIDIASIS; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DEVICE INFECTION; DEVICE REMOVAL; DISEASE EXACERBATION; FOLLOW UP; HUMAN; IMPLANT; INFANT; LUNG DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATIENT CODING; PRIORITY JOURNAL; RELIABILITY; RETROSPECTIVE STUDY; RISK FACTOR; SAFETY; SEPTICEMIA; SURVIVAL; THROMBOSIS; VASCULAR ACCESS;

ANTI-BACTERIAL AGENTS; BLOOD SPECIMEN COLLECTION; CATHETERS, INDWELLING; CHILD; CYSTIC FIBROSIS; FOCAL INFECTION; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; PARENTERAL NUTRITION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; THROMBOSIS; TIME FACTORS;

EID: 12144290004     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00052504     Document Type: Article

References (26)

1. Pattison J, Heaf DP. Totally implantable vascular access in treatment of cystic fibrosis. Lancet 1986; i: 799.
2. Stead RJ, Davidson TI, Duncan FR, Hodson M, Batten JC. Use of a totally implantable system for venous access in cystic fibrosis. Thorax 1987; 42: 149-150.
3. Kariyawasam HH, Pepper JR, Hodson ME, Geddes DM. Experience of totally implantable venous access devices (TIVADs) in adults with cystic fibrosis over a 13-year period. Respir Med 2000; 94: 1161-1165.
4. Aitken ML, Tonelli MR. Complications of indwelling catheters in cystic fibrosis. A 10 year-review. Chest 2000; 118: 1598-1602.
5. Morris JB, Occhionero ME, Gauderer MWL, Stern RC, Doershuk CF. Totally implantable vascular access devices in cystic fibrosis: A four-year experience with fifty-eight patients. J Pediatr 1990; 117: 82-85.
6. Ball AB, Duncan FR, Foster FJ, Davidson TI, Watkins RM, Hodson ME. Long term venous access using a totally implantable drug delivery system in patients with cystic fibrosis and bronchiectasis. Respir Med 1989; 83: 429-431.
7. Sola JE, Stone MM, Wise B, Colombani P. Atypical thrombotic and septic complications of totally implantable venous access devices in patients with cystic fibrosis. Pediatr Pulmonol 1992; 14: 239-242.
8. Yung B, Campbell JA, Elborn JS, Harvey JS, Shale DJ. Totally implantable venous access devices in adult patients with cystic fibrosis. Respir Med 1996; 90: 353-356.
9. Rodgers HC, Liddle K, Nixon SJ, Innes JA, Greening AP. Totally implantable venous access devices in cystic fibrosis: complications and patients opinions. Eur Respir J 1998; 12: 217-220.
10. Burdon J, Conway SP, Murchan P, Lansdown M, Kester RCK. Five years' experience of PAS port intravenous access system in adult cystic fibrosis. Eur Respir J 1998; 12: 212-216.
11. Deerojanawong J, Sawyer SM, Fink AM, Stokes KB, Robertson CF. Totally implantable venous access devices in children with cystic fibrosis: Incidence and type of complications. Thorax 1998; 53: 285-289.
12. Cassey J, Ford WDA, O'Brien LO, Martin AJ. Totally implantable system for venous access in children with cystic fibrosis. Clin Pediatr 1988; 27: 91-95.
13. Essex-Cater A, Gilbert J, Robinson T. Littlewood JM. Totally implantable venous access systems in paediatric practice. Arch Dis Child 1989; 64: 119-123.
14. Peckham DG, Hill J, Manhire AR, Knox AJ. 1. Resolution of superior vena cava obstruction following thrombolytic therapy in a patient with cystic fibrosis and a long-term indwelling catheter. Respir Med 1994; 88: 627-629.
15. Yung B, Elborn JS, Campbell IA, Summers Y, Beckles M, Woodcock AA. Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis. Thorax 1997; 52: 98-99.
16. Allen ED, Mick AB, Nicol J, McCoy K. Prolonged parenteral nutrition for cystic fibrosis patients. Nutr Clin Pract 1995; 10: 73-79.
17. Bonacorsi S, Munck A, Ovetchkine P, et al. In situ management and molecular analysis of candidemia related to a totally implantable vascular access in a cystic fibrosis patient. J Infect 1996; 93: 49-51.
18. Horn CK, Conway SP. Candidaemia: Risk factors in patients with cystic fibrosis who have totally implantable venous access systems. J Infect 1993; 26: 127-132.
19. Fahy JV, Keoghan MT, Crummy EJ, Fitzgerald MX. Bacteraemia and fungaemia in adults with cystic fibrosis. J Infect 1991; 22: 241-245.
20. La Quaglia MP, Lucas A, Thaler HT, et al. A prospective analysis of vascular access device-related infections in children. J Pediatr Surg 1992; 27: 840-842.
21. Ross P, Ehrenkranz R, Kleinman CS, et al. Thrombus associated with central venous catheters in infants and children. J Pediatr Surg 1989; 24: 253-256.
22. Brothers TE, Von Moll LK, Niederhuber JE, et al. Experience with subcutaneous infusion ports on 300 patients. Gynecol Obstet 1988; 166: 295-301.
23. Biffi R, de Brand F, Orsi F, et al. Totally implantable central venous access ports for long-term chemotherapy: A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Annal Oncol 1998; 9: 767-773.
24. Abdul-Rauf A, Gauderer M, Chiarucci K, et al. Long-term central venous access in patients with sickle cell disease. J Pediatr Hematol Oncol 1995; 17: 342-345.
25. Wurzal CL, Halon K, Feldman JG, et al. Infection rates of Broviac-Hickman catheters and implantable venous devices. Am J Dis Child 1988; 142: 536-540.
26. Goodman HE, Brettle RP, Stevenson B, et al. Central venous catheters in patients with AIDS. Int J STD AIDS 1997; 8: 417-422.